Genmab As Stock Book Value Per Share
| GMAB Stock | USD 20.71 0.24 1.17% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Stock. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 484.00 | 508.20 | |
| Tangible Book Value Per Share | 482.45 | 506.58 |
Genmab | Book Value Per Share |
Genmab AS Company Book Value Per Share Analysis
Genmab AS's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Genmab AS Book Value Per Share | 502.60 X |
Most of Genmab AS's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Genmab Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Genmab AS is extremely important. It helps to project a fair market value of Genmab Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Genmab AS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genmab AS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genmab AS's interrelated accounts and indicators.
Click cells to compare fundamentals
Genmab Book Value Per Share Historical Pattern
Today, most investors in Genmab AS Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Genmab AS's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Genmab AS book value per share as a starting point in their analysis.
Genmab AS Book Value Per Share |
| Timeline |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Genmab Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Genmab AS is about 502 times. This is 29664.76% lower than that of the Biotechnology sector and notably lower than that of the Health Care industry. The book value per share for all United States stocks is 73.98% higher than that of the company.
Genmab Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab AS's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in book value per share category among its peers.
Genmab AS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Genmab AS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Genmab AS's managers, analysts, and investors.Environmental | Governance | Social |
Genmab Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 10.73 B | ||||
| Shares Outstanding | 635.14 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 8.40 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 2.86 X | ||||
| Price To Sales | 0.66 X | ||||
| Revenue | 16.47 B | ||||
| Gross Profit | 14.6 B | ||||
| EBITDA | 5.56 B | ||||
| Net Income | 4.35 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 770 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 502.60 X | ||||
| Cash Flow From Operations | 7.38 B | ||||
| Short Ratio | 1.84 X | ||||
| Earnings Per Share | 1.02 X | ||||
| Price To Earnings To Growth | 0.70 X | ||||
| Target Price | 37.39 | ||||
| Number Of Employees | 2.63 K | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 13.05 B | ||||
| Total Asset | 35.29 B | ||||
| Retained Earnings | 19.02 B | ||||
| Working Capital | 30.66 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
| Net Asset | 35.29 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Piotroski F Score and Genmab AS Altman Z Score analysis. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.